---
figid: PMC8450413__fgene-12-681053-g005
figtitle: Epigenetic Regulation of the Wnt/Beta-Catenin Signaling Pathway in Cancer
organisms:
- Danio rerio
- Xenopus laevis
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
- Lareunionomyces loeiensis
- Mouse mammary tumor virus
pmcid: PMC8450413
filename: fgene-12-681053-g005.jpg
figlink: /pmc/articles/PMC8450413/figure/F5/
number: F5
caption: Chemotherapeutic interventions targeting the components of the Wnt signaling
  pathway. Drugs leading to the activation of the Wnt response inhibitors and repression
  of the Wnt response activators are being used as therapeutic agents for cancer therapy
  (or are under clinical trials). Wnt1 monoclonal antibody (MAb), Vantictumab and
  Ipafricept target the upstream regulators of the Wnt pathway. WNT974 blocks PORCN
  which prevents processing of Wnt ligands. IWR-1 and XAV939 act by activating AXIN,
  thereby stabilizing the Wnt destruction complex. PRI-724 acts by inhibiting the
  interaction of β-catenin with CBP/p300. PKF115-584, CGPO49090, PKF222-815, iCRT3,
  iCRT5, and iCRT14 act by inhibiting interaction of β-catenin with TCF/LEF.
papertitle: Epigenetic Regulation of the Wnt/β-Catenin Signaling Pathway in Cancer.
reftext: Ankita Sharma, et al. Front Genet. 2021;12:681053.
year: '2021'
doi: 10.3389/fgene.2021.681053
journal_title: Frontiers in Genetics
journal_nlm_ta: Front Genet
publisher_name: Frontiers Media S.A.
keywords: Wnt signaling | β-catenin | YAP | epigenetics | cancer | therapeutics
automl_pathway: 0.9393677
figid_alias: PMC8450413__F5
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
- Danio rerio
- Drosophila melanogaster
redirect_from: /figures/PMC8450413__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8450413__fgene-12-681053-g005.html
  '@type': Dataset
  description: Chemotherapeutic interventions targeting the components of the Wnt
    signaling pathway. Drugs leading to the activation of the Wnt response inhibitors
    and repression of the Wnt response activators are being used as therapeutic agents
    for cancer therapy (or are under clinical trials). Wnt1 monoclonal antibody (MAb),
    Vantictumab and Ipafricept target the upstream regulators of the Wnt pathway.
    WNT974 blocks PORCN which prevents processing of Wnt ligands. IWR-1 and XAV939
    act by activating AXIN, thereby stabilizing the Wnt destruction complex. PRI-724
    acts by inhibiting the interaction of β-catenin with CBP/p300. PKF115-584, CGPO49090,
    PKF222-815, iCRT3, iCRT5, and iCRT14 act by inhibiting interaction of β-catenin
    with TCF/LEF.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PORCN
  - RPSA
  - LRP1
  - PTPRA
  - MVP
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - SLC7A6OS
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - BCAS3
  - AXIN1
  - AXIN2
  - CTNNB1
  - CSNK1A1
  - APC
  - PROC
  - EP300
  - CREBBP
  - EIF4E
  - OPN1LW
  - PAG1
  - PCBP4
  - HNF4A
  - Porcn
  - Lrp1
  - Mvp
  - Txlng
  - Wnt1
  - Axin1
  - Ctnnb1
  - Csnk1a1
  - Apc
  - Ep300
  - Crebbp
  - Pag1
  - Cytip
  - porcn
  - porcnl
  - cby1
  - wnt1
  - ctnnb1
  - csnk1a1
  - apc
  - elk4
  - arr
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - fz
  - Axn
  - arm
  - CkIalpha
  - Apc2
  - Fs(3)Apc
  - osa
  - nej
  - CBP
  - eIF4E1
  - pan
---
